Trial Profile
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 10 Jan 2023 Planned End Date changed from 7 Dec 2022 to 7 Dec 2024.
- 10 Jan 2023 Planned primary completion date changed from 7 Dec 2022 to 7 Dec 2023.
- 07 Jun 2022 Primary endpoint (1 year progression-free survival (PFS)) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.